RxDoctor Payments Data

Jacqueline Morgan, MD

Gynecologic Oncology · Wichita, KSNPI 1295837904

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.3% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Intuitive Surgical at 26.4% of the total. Reporting peaked in 2024 at $387 and has fallen 79.7% since, to $79 in 2025.

$1,527in general payments, 2019–2025

Across 40 payments — averaging $38.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$403
  • Genmab U.S., Inc.$249
  • Eisai Inc.$150
  • Conmed Corporation$122
  • Myriad Genetic Laboratories, Inc.$118
  • Davol Inc.$101
  • plus $385 from 7 others

What the payments were for

  • Travel & lodging$372%
  • Food & beverage$1,42593%
  • Education$654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecologic oncology providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$150,273
Medicare patients
309
Services billed
842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban33$27,469
Megestrol Acetate79$2,806
PremarinEstrogens, Conjugated12$2,416
Letrozole42$1,082
Oxycodone Hcl91$594
Estradiol17$526
Dexamethasone69$328
Ondansetron Hcl58$291
Gabapentin21$204
Tamoxifen Citrate15$197
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$193
Hydromorphone Hcl25$168
Tramadol Hcl21$95
Triamcinolone Acetonide12$95
Venlafaxine Hcl ErVenlafaxine Hcl13$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$12$2,41612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecologic oncology providers in Kansason file to place this against a meaningful peer group, so we don't.

Other gynecologic oncology in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →